GlassScriptPhysician profile
Thomas M Rampy
NPI 1588637136
$16,308.47
in general payments reported to CMS, 2019-2025
55 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $1,879 · 2021: $2,744 · 2022: $2,713 · 2023: $2,299 · 2024: $2,296 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,825 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,824.85 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,159.16 | 2019-2025 | |
| Emd Serono, INC. | $1,967.46 | 2019-2025 | Mavenclad |
| Abbvie INC. | $1,193.09 | 2021-2025 | |
| Biogen, INC. | $1,136.44 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Lilly USA, LLC | $917.92 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Pfizer INC. | $759.20 | 2019-2025 | |
| Celgene Corporation | $654.43 | 2021-2025 | Zeposia |
| Ucb, INC. | $610.00 | 2019-2024 | Fintepla, Rystiggo, Briviact |
| Amgen INC. | $565.48 | 2019-2025 | Uplizna, Aimovig |
| Genzyme Corporation | $447.51 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $447.07 | 2021 | |
| Lundbeck LLC | $352.27 | 2020-2025 | Vyepti |
| Genentech USA, INC. | $346.59 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Mallinckrodt Hospital Products INC. | $328.88 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $310.17 | 2019-2024 | Ultomiris |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Rampy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.